EV Biotech and Synonym have forged a powerful partnership, combining their strengths to accelerate the development and commercialization of cutting-edge biomaterials.
EV Biotech’s innovative platform utilizes computational prediction and lab-based confirmation to swiftly design and optimize microbial strains for biomaterial production. This empowers their customers to access Synonym’s advanced biomanufacturing platform, significantly speeding up the scale-up and commercialization process.
On the other hand, Synonym’s customers gain access to EV Biotech’s technology, enabling them to significantly reduce strain engineering costs, shorten time to market, and achieve exceptional R&D outcomes.
This collaboration fosters a synergistic environment, propelling the biomaterial industry forward by decreasing development timelines and costs, optimizing biomaterial production through advanced strain engineering, and accelerating the commercialization of novel biomaterials. This strategic partnership signifies a significant step towards revolutionizing the biomaterial landscape. By leveraging each other’s expertise, EV Biotech and Synonym pave the way for sustainable and innovative solutions across various industries.
“For bioproducts to seamlessly integrate into our daily lives, precision is essential for companies right from the initial stages of strain development. EV Biotech’s state-of-the-art computational design technology empowers companies to enhance strain performance, effectively reducing their R&D time by half and accelerating their time to market,” said Joshua Lachter, Synonym’s Co-Founder and Chief Business Officer.
“Synonym’s expertise in techno-economic analysis, lifecycle assessment, and facility development and financing will help our customers commercialize faster, cheaper, and more sustainably. We are excited to help more companies scale up successfully by identifying their commercial bioprocess milestones through Synonym’s platform and helping them reach their strain and fermentation targets using ours,” added Linda Dijkshoorn, Chief Commercial Officer (CCO) and Founder of EV Biotech.
